Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 445-451

  Kayser, Gian ^a   Schulte Uentrop, Luzie ^a   Sienel, Wulf ^a   Werner, Martin ^a   Fisch, Paul ^a   Passlick, Bernward ^a   Hausen, Axel zur ^b   Stremmel, Christian ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Immunohistochemistry; Immunology; Lung cancer; Prognosis; T lymphocyte; Tissue micro array

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; COHORT ANALYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; STROMA CELL; T LYMPHOCYTE ACTIVATION; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84860536647     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.01.004     Document Type: Article

References (38)

1. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
2. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345-352.
3. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
4. Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296.
5. Thompson C., Powrie F. Regulatory T cells. Curr Opin Pharmacol 2004, 4:408-414.
6. Nishikawa H., Jager E., Ritter G., Old L.J., Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 2005, 106:1008-1011.
7. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182:18-32.
8. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
9. Hiraoka N., Onozato K., Kosuge T., Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006, 12:5423-5434.
10. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-4772.
11. Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.L., et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002, 168:4272-4276.
12. Petersen R.P., Campa M.J., Sperlazza J., Conlon D., Joshi M.B., Harpole D.H., et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872.
13. Shimizu K., Nakata M., Hirami Y., Yukawa T., Maeda A., Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010, 5:585-590.
14. Tao H., Mimura Y., Aoe K., Kobayashi S., Yamamoto H., Matsuda E., et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 2011.
15. Gao Q., Qiu S.J., Fan J., Zhou J., Wang X.Y., Xiao Y.S., et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586-2593.
16. Alvaro T., Lejeune M., Salvado M.T., Bosch R., Garcia J.F., Jaen J., et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005, 11:1467-1473.
17. Salama P., Phillips M., Grieu F., Morris M., Zeps N., Joseph D., et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27:186-192.
18. Mizukami Y., Kono K., Kawaguchi Y., Akaike H., Kamimura K., Sugai H., et al. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 2008, 98:148-153.
19. Sobin L.H., Gospodarowicz M.K., Wittekind C. TNM classification of malignant tumours (UICC international union against cancer) 2009, John Wiley & Sons, Chichester. 7th ed.
20. Tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Mueller-Hermelink, C.C. Harris (Eds.).
21. Bates G.J., Fox S.B., Han C., Leek R.D., Garcia J.F., Harris A.L., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006, 24:5373-5380.
22. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
23. Kono K., Kawaida H., Takahashi A., Sugai H., Mimura K., Miyagawa N., et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006, 55:1064-1071.
24. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102:18538-18543.
25. Woo Y.L., Sterling J., Crawford R., van der Burg S.H., Coleman N., Stanley M. FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies. J Clin Pathol 2008, 61:969-971.
26. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
27. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002, 2:389-400.
28. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+ CD25 high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
29. Kiniwa Y., Miyahara Y., Wang H.Y., Peng W., Peng G., Wheeler T.M., et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007, 13:6947-6958.
30. Li J., Huang Z.F., Xiong G., Mo H.Y., Qiu F., Mai H.Q., et al. Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma. J Transl Med 2011, 9:189.
31. Manrique S.Z., Correa M.A., Hoelzinger D.B., Dominguez A.L., Mirza N., Lin H.H., et al. Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth. J Exp Med 2011, 208:1485-1499.
32. Erdman S.E., Poutahidis T., Tomczak M., Rogers A.B., Cormier K., Plank B., et al. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol 2003, 162:691-702.
33. Erdman S.E., Sohn J.J., Rao V.P., Nambiar P.R., Ge Z., Fox J.G., et al. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 2005, 65:3998-4004.
34. Martinet L., Garrido I., Filleron T., Le Guellec S., Bellard E., Fournie J.J., et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011, 71:5678-5687.
35. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
36. Fischer K., Hoffmann P., Voelkl S., Meidenbauer N., Ammer J., Edinger M., et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007, 109:3812-3819.
37. Kayser G., Kassem A., Sienel W., Schulte-Uentrop L., Mattern D., Aumann K., et al. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol 2010, 5:22.
38. Viard-Leveugle I., Veyrenc S., French L.E., Brambilla C., Brambilla E. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 2003, 201:268-277.